Palvella Therapeutics, Inc. Operating Lease, Payments
Palvella Therapeutics, Inc. (PVLA) reported Operating Lease, Payments of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2024-11-13
- Palvella Therapeutics, Inc. operating lease, payments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, payments for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, payments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, payments for the quarter ending 2023-12-31 was $600.00K, a 25.00% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, payments for fiscal 2023 was $2.20M, a 8.33% decline from fiscal 2022.
- Palvella Therapeutics, Inc. operating lease, payments for fiscal 2022 was $2.40M, a 7.69% decline from fiscal 2021.
- Palvella Therapeutics, Inc. operating lease, payments for fiscal 2021 was $2.60M, a 18.18% increase from fiscal 2020.
- Palvella Therapeutics, Inc. operating lease, payments for fiscal 2020 was $2.20M, a 340.00% increase from fiscal 2019.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $600.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $600.00K derived: sum of 3 quarters · filed 2024-08-14 | $1.10M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $600.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.10M derived: sum of 3 quarters · filed 2024-11-13 | $1.60M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.10M derived: sum of 2 quarters · filed 2024-11-13 | $1.60M derived: sum of 3 quarters · filed 2024-11-13 | $2.20M 10-K · filed 2024-03-29 |
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-13 | $1.00M derived: sum of 2 quarters · filed 2024-11-13 | $1.60M 10-Q · filed 2024-11-13 | $2.30M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-14 | $1.10M 10-Q · filed 2024-08-14 | $1.80M derived: sum of 3 quarters · filed 2024-08-14 | $2.30M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-15 | $1.30M derived: sum of 2 quarters · filed 2024-05-15 | $1.80M derived: sum of 3 quarters · filed 2024-05-15 | $2.40M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.30M derived: sum of 2 quarters · filed 2024-03-29 | $1.90M derived: sum of 3 quarters · filed 2024-03-29 | $2.40M 10-K · filed 2024-03-29 |
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-14 | $1.10M derived: sum of 2 quarters · filed 2023-11-14 | $1.60M 10-Q · filed 2023-11-14 | $2.40M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-10 | $1.10M 10-Q · filed 2022-08-04 | $1.90M derived: sum of 3 quarters · filed 2023-08-10 | $2.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-11 | $1.30M derived: sum of 2 quarters · filed 2023-05-11 | $1.90M derived: sum of 3 quarters · filed 2023-05-11 | $2.50M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.30M derived: sum of 2 quarters · filed 2023-03-31 | $1.90M derived: sum of 3 quarters · filed 2023-03-31 | $2.60M 10-K · filed 2023-03-31 |
| 2021-09-30 | $600.00K 10-Q · filed 2022-11-04 | $1.20M derived: sum of 2 quarters · filed 2022-11-04 | $1.90M 10-Q · filed 2022-11-04 | $2.60M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $600.00K 10-Q · filed 2022-08-04 | $1.30M 10-Q · filed 2022-08-04 | $2.00M derived: sum of 3 quarters · filed 2022-08-04 | $2.60M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $700.00K 10-Q · filed 2022-05-11 | $1.40M derived: sum of 2 quarters · filed 2022-05-11 | $2.00M derived: sum of 3 quarters · filed 2022-05-11 | $2.60M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $1.30M derived: sum of 2 quarters · filed 2022-03-02 | $1.90M derived: sum of 3 quarters · filed 2022-03-02 | $2.20M 10-K · filed 2022-03-02 |
| 2020-09-30 | $600.00K 10-Q · filed 2021-11-02 | $1.20M derived: sum of 2 quarters · filed 2021-11-02 | $1.50M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $600.00K 10-Q · filed 2021-08-05 | $900.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $300.00K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $500.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |